Loading patent…
AssigneeSantaris Pharma A/S
InventorsCharlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
Estimating the term…
Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analog, or Locked Nucleic Acid (LNA) or a combination thereof.
A compound of 16 to 50 nucleotides or nucleotide analogues, comprising SEQ ID NO:
A compound represented by the formula:
A compound selected from:
Dependencies are inferred from the claim text.